Table 2.
Univariate and multivariate analysis of the prognostic value of the 2‐gene signature in terms of RFS in UPS/MFS
| Parameters | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| p | HR | 95% CI (lower/upper) | p | HR | 95% CI (lower/upper) | |||
| Pathological tumour size (mm) | <0.001 | 1.094 | 1.040 | 1.151 | <0.001 | 1.102 | 1.044 | 1.164 |
| Pharmaceutical drug adjuvant therapy | ||||||||
| Yes (N = 10) | 1.000 | |||||||
| No (N = 38) | 0.023 | 0.387 | 0.171 | 0.877 | ||||
| FNCLCC grade | ||||||||
| 1/2 (N = 18) | 1.000 | |||||||
| 3 (N = 43) | 0.038 | 2.736 | 1.055 | 7.097 | ||||
| 2‐gene signature (ITGA10/PPP2R2B) | <0.001 | 2.717 | 1.856 | 3.976 | <0.001 | 2.966 | 1.995 | 4.410 |
Multivariate analysis was conducted by forward: LR method.
Bold value indicates P < .05.